Free tool
FAERS Monitor: Xultophy 100/3.6
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming BLA 208583 or its brand name (Xultophy 100/3.6, Insulin Degludec, Liraglutide). Reports on generic versions are filed under their own applications.
Reports
1,658
Serious
1,268
76% of reports
Hospitalization
648
Death reported
90
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- blood glucose increased192
- nausea122
- acute kidney injury88
- diarrhoea87
- vomiting87
- hypoglycaemia73
- glycosylated haemoglobin increased62
- lactic acidosis58
- decreased appetite53
- asthenia50
- dizziness48
- hyperglycaemia47
- weight decreased44
- blood glucose decreased43
- hospitalisation43
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2016 | 3 |
| 2017 | 125 |
| 2018 | 229 |
| 2019 | 198 |
| 2020 | 150 |
| 2021 | 202 |
| 2022 | 149 |
| 2023 | 116 |
| 2024 | 166 |
| 2025 | 217 |
| 2026 | 103 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,052,501 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| glycosylated haemoglobin increasedSignal | 62 | 31.2 | 24.5 | 1,783 |
| lactic acidosisSignal | 58 | 22.8 | 17.7 | 1,184 |
| hypoglycaemiaSignal | 73 | 19.1 | 15.3 | 1,237 |
| hyperglycaemiaSignal | 47 | 16.4 | 12.4 | 664 |
| blood glucose increasedSignal | 192 | 12.9 | 11.3 | 2,120 |
| blood glucose decreasedSignal | 43 | 11.4 | 8.5 | 397 |
| acute kidney injurySignal | 88 | 7.3 | 6.0 | 475 |
| hospitalisationSignal | 43 | 3.6 | 2.6 | 77 |
| decreased appetiteSignal | 53 | 2.9 | 2.2 | 65 |
| vomitingSignal | 87 | 2.3 | 1.9 | 67 |
| weight decreased | 44 | 2.0 | 1.5 | 21 |
| nausea | 122 | 2.0 | 1.6 | 58 |
| diarrhoea | 87 | 1.7 | 1.4 | 26 |
| asthenia | 50 | 1.7 | 1.3 | 14 |
| dizziness | 48 | 1.2 | 0.9 | 2 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.